Factor V, a glycoprotein is usually seen in the alpha granules of platelets and in plasma.[1]
Factor Va is the activated form of factor V and the cofactor of Xa. It is a component of the prothrombinase complex.
Biochem./physiol. Wirkung
Factor V is a key component in blood coagulation systems, where deficiencies can inhibit thrombin generation and affect hemostasis. It has been used in studies of coagulopathic bleeding which occurs following injury and is a leading cause of hospital deaths.
Factor Va serves as a receptor and positive effector of factor Xa. Hence it can efficiently help in the conversion of prothrombin to thrombin.[2]
One unit is equivalent to the Factor V activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
Physikalische Form
Aqueous solution containing 50% (v/v) glycerol and 5mM CaCl2
Haftungsausschluss
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
The intrinsic and extrinsic pathways of the coagulation cascade converge to a common step where the prothrombinase complex, comprising the enzyme factor Xa (fXa), the cofactor fVa, Ca2+ and phospholipids, activates the zymogen prothrombin to the protease thrombin. The reaction
Coagulation factor V (fV) is the precursor of fVa, which, together with fXa, Ca2+, and phospholipids, defines the prothrombinase complex and activates prothrombin in the penultimate step of the coagulation cascade. We solved the cryogenic electron microscopy (cryo-EM) structures of
The Journal of trauma, 71(5 Suppl 1), S427-S434 (2011-12-17)
Coagulopathic bleeding is a leading cause of in-hospital death after injury. A recently proposed transfusion strategy calls for early and aggressive frozen plasma transfusion to bleeding trauma patients, thus addressing trauma-associated coagulopathy (TAC) by transfusing clotting factors (CFs). This strategy
Fragen
Bewertungen
★★★★★ Kein Beurteilungswert
Aktive Filter
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..